Funding Momentum Virtuoso Surgical has secured NIH SBIR funding of 1.8 million dollars over two years and has highlighted NIH-backed investments in its endoscopic robotic system. This demonstrates credibility and a healthy funding runway that can support clinical trials and hospital-based pilots. Leverage these funding engagements to engage research departments, grant offices, and purchasing committees at academic medical centers and teaching hospitals.

Board Expansion A new board member joined in November 2025, bringing healthcare entrepreneurship and investment expertise. This expands access to strategic partners, potential customers, and distribution channels through board networks. Use the board as a channel to reach regional health systems, venture capital firms, and potential pilot sites for the Virtuoso system.

Clinical Evidence Since the 2023 system launch and NIH-funded tracheal lesion experiments, there is momentum for clinical validation and outcomes data. Hospitals seeking robotics solutions will want pilot programs, performance metrics, and case studies. Prepare value-focused materials highlighting reduced invasiveness, precision, and potential reductions in operative time and costs, and target oncology, airway, ENT, and minimally invasive surgery programs.

Cost Advantage The mission to deliver dexterous, accurate, and cost-effective endoscopic robotic tools positions Virtuoso as a disruptive option against larger players. Hospitals with capital constraints will respond to ROI analyses, total cost of ownership, and service packages that lower the risk of adoption. Offer flexible purchasing, training, and maintenance options to accelerate procurement.

Regional Focus Based in Nashville, Virtuoso has proximity to the Southeastern healthcare market and academic centers, enabling regional pilots and collaboration with translational research programs. Target regional medical centers, VA campuses, and community hospitals with active minimally invasive programs in oncology and airway surgery. Build a pathway to scale from regional wins to broader national adoption through partnerships and sponsorship of clinical trials.